Table 1 Demographics of the PA patients in the black, grey, and white groups
|  | Black (n = 63) | Grey (n = 79) | White (n = 63) | p-value |
|---|---|---|---|---|
Mean age, years (SD) | 48.4 (10.9) | 50.6 (10.6) | 54.2 (11.6) | 0.0125 |
Males, n (%) | 35 (55.6%) | 36 (45.6%) | 29 (46.0%) | 0.433 |
Mean body weight, kg (SD) | 69.0 (14.1) | 69.2 (16.8) | 69.0 (15.0) | 0.9948 |
Mean body height, cm (SD) | 165.7 (8.8) | 164.1 (9.0) | 163.5 (9.0) | 0.3477 |
Mean BMI, kg/m2 (SD) | 25.0 (4.0) | 25.5 (4.5) | 25.5 (3.9) | 0.7223 |
Mean waist line, cm (SD) | 84.9 (11.4) | 85.6 (13.5) | 84.9 (11.9) | 0.931 |
Mean buttocks width, cm (SD) | 96.8 (7.3) | 97.1 (11.1) | 96.8 (9.4) | 0.9674 |
Mean blood pressure, mmHg (SD) | ||||
 Systolic | 157.9 (22.7) | 154.9 (19.4) | 150.2 (19.0) | 0.1059 |
 Diastolic | 95.5 (14.2) | 92.3 (12.3) | 90.2 (13.5) | 0.0869 |
Medical history, n (%) | ||||
 DM | 4 (6.35%) | 14 (17.72%) | 10 (15.87%) | 0.103 |
 Hyperlipidemia | 11 (17.46%) | 19 (24.05%) | 18 (28.57%) | 0.333 |
 Hyperthyroidism | 0 | 1 (1.27%) | 0 | 1 |
 Hypothyroidism | 1 (1.59%) | 0 | 2 (3.17%) | 0.286 |
 Atrial fibrillation | 2 (3.17%) | 3 (3.80%) | 1 (1.59%) | 0.877 |
 CAD/MI | 0 | 0 | 0 |  |
 CVA | 4 (6.35%) | 5 (6.33%) | 4 (6.35%) | 1 |
 Renal stone | 6 (9.52%) | 5 (6.33%) | 3 (4.76%) | 0.612 |
 Smoking history | 7 (11.11%) | 5 (6.33%) | 11 (17.46%) | 0.114 |
 Family history of HTN | 35 (55.56%) | 60 (75.95%) | 44 (69.84%) | 0.033 |
 Duration of HTN, year(s) (SD) | 5.8 (6.6) | 8.2 (7.1) | 8.4 (8.7) | 0.084 |
 CCI (SD) | 1.5 (1.5) | 1.5 (1.3) | 1.5 (1.4) | 0.9692 |
 AVS LI (SD) | 4.61 (6.35) | 5.44 (6.43) | 2.91 (3.43) | 0.3721 |
 Contralateral suppression, n (%) | 3 (4.8%) | 2 (2.53%) | 0 | 0.277 |
 Maximum adrenal nodule diameter, cm (SD) | 1.9 (1.2) | 1.8 (1.1) | 1.7 (0.7) | 0.84 |
 Mean number of antihypertensive agents, n (SD) | 2.0 (1.3) | 2.2 (1.1) | 1.9 (1.3) | 0.3229 |
 ACEI, n (%) | 2 (3.2%) | 0 | 0 | 0.187 |
 α-blocker, n (%) | 18 (28.6%) | 16 (20.3%) | 14 (22.2%) | 0.491 |
 β-blocker, n (%) | 22 (34.9%) | 29 (36.7%) | 23 (36.5%) | 0.973 |
 ARB, n (%) | 25 (4.0%) | 39 (4.9%) | 24 (3.8%) | 0.331 |
 CCB, n (%) | 39 (61.9%) | 58 (73.4%) | 39 (61.9%) | 0.237 |
 Aldactone, n (%) | 15 (2.4%) | 23 (2.9%) | 11 (1.7%) | 0.27 |
 Vasodilator, n (%) | 6 (9.5%) | 5 (6.3%) | 3 (4.8%) | 0.612 |
 Diuretics, n (%) | 2 (3.2%) | 6 (7.6%) | 7 (11.1%) | 0.215 |
Pre-operative | ||||
 Mean serum potassium, mEq/L (SD) | 3.5 (0.6) | 3.6 (0.6) | 3.9 (0.5) | 0.0006 |
 Mean serum creatinine, mg/dL (SD) | 0.9 (0.5) | 0.9 (0.3) | 0.9 (0.3) | 0.5267 |
 Mean plasma aldosterone, ng/dl (SD) | 57.0 (32.3) | 60.5 (49.9) | 42.4 (24.4) | 0.0159 |
 Mean PRA, ng/ml/hr (SD) | 0.5 (0.9) | 0.5 (0.7) | 0.5 (0.9) | 0.7957 |
 Mean ARR (SD) | 756.9 (1958.9) | 1136.8(2425.1) | 971.9 (2100.8) | 0.5915 |
Post-operative 6th month | ||||
 Mean serum potassium, mEq/L (SD) | 4.4 (0.5) | 4.4 (0.4) | 4.1 (0.4) | 0.0006 |
 Mean serum creatinine, mg/dL (SD) | 1.2 (0.7) | 1.0 (0.4) | 1.0 (0.5) | 0.0755 |
 Mean plasma aldosterone, ng/dl (SD) | 26.2 (19.5) | 31.8 (21.8) | 35.0 (23.3) | 0.1022 |
 Mean PRA, ng/ml/hr (SD) | 3.6 (3.0) | 2.1 (2.2) | 1.9 (3.0) | 0.0023 |
 Mean ARR (SD) | 48.3 (117.8) | 94.3 (278.3) | 196.1 (608.9) | 0.118 |
Post-operative 12th month | ||||
 Mean serum potassium, mEq/L (SD) | 4.3 (0.5) | 4.3 (0.4) | 4.2 (0.4) | 0.113 |
 Mean serum creatinine, mg/dL (SD) | 1.2 (0.9) | 1.0 (0.4) | 1.0 (1.0) | 0.1545 |
 Mean plasma aldosterone, ng/dl (SD) | 27.7 (20.1) | 39.5 (25.2) | 32.4 (16.1) | 0.01 |
 Mean PRA, ng/ml/hr (SD) | 3.3 (2.3) | 3.5 (4.8) | 2.2 (3.0) | 0.1325 |
 Mean ARR (SD) | 88.1 (443.9) | 123.6 (425.7) | 304.7 (1078.8) | 0.2253 |
